重庆医学2013，Vol.42Issue(12)：1350-1351,1354,3.DOI:10.3969/j.issn.1671-8348.2013.12.012
核苷类似物抗病毒治疗后HBeAg(-)/(+)患者肝癌发生的临床观察
Clinical observation of the incidence of hepatocellular carcinoma in HBeAg(-)/(+) chronic hepatitis B patients with nucleoside analogue therapy
摘要
Abstract
Objective To evaluate the correlation between hepatocellular carcinoma incidence and HBeAg( —)/( + ) in chronic hepatitis B patients with long term nucleoside analogue therapy. Methods A retrospective study included 751 chronic hepatitis B patients with long term nucleoside analogue therapy from September 2006 to October 2012 in this hospital. HBeAg(—) and HBeAg ( + ) were selected to evaluate the incidence of hepatocellular carcinoma. All subjects underwent anti viral therapy with no less than five years. Results The total incidence of hepatocellular carcinoma was 5. 19% ,and the incidence in HBeAg( + ) chronic hepatitis B patients (without liver cirrhosis) was 1. 91% ,while the incidence in HBeAg(—) patients was 5. 31% ,and the incidence of hepato cellular carcinoma was much higher in patients (without liver cirrhosis) of HBeAg( —). Conclusion Long term therapy with nucle osides can reduce but not eliminate the hepatocellular carcinoma risk in patients with chronic hepatitis B, especially those with HBeAg( —). HBeAg negativity is a significant risk factor for the development of hepatocellular carcinoma in chronic hepatitis B pa tients (without liver cirrhosis).关键词
核苷类/癌,肝细胞/肝炎,乙型,慢性Key words
nucleosides/ carcinoma, hepatocellular/ hepatitis B, chronic引用本文复制引用
杨斌,占劲松,宋建新..核苷类似物抗病毒治疗后HBeAg(-)/(+)患者肝癌发生的临床观察[J].重庆医学,2013,42(12):1350-1351,1354,3.基金项目
吴阶平医学基金会肝病医学部肝病实验诊断研究基金(LDWMF-SY-2011C010). （LDWMF-SY-2011C010）
